EUVIMEDEUVIMED entdecken
Crossref

Hypoxia-Induced MicroRNAs Confer Survival Advantage in Bladder Cancer by Fine-Tuning Oncogenic Pathways

Takaya Ohno, Yuki Nakajima, Yuki Yoshikawa, Takuya Tsujino, Ryoichi Maenosono, Ko Nakamura, Tomoaki Takai, Taizo Uchimoto, Tatsuo Fukushima, Kazuki Nishimura, Yusuke Yano, Takuya Higashio und 4 weitere

Oncology · 07.04.2026 · 1-9

DOI: 10.1159/000551754 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oncology, online erschienen am 07.04.2026. Verfasst von Takaya Ohno und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Osaka Medical and Pharmaceutical University, Takatsuki, Japan. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, MicroRNAs, Hypoxia. Die Arbeit nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Bladder cancer (BC) is influenced by hypoxic conditions, which promote tumor progression and resistance to therapy. MicroRNAs (miRNAs) play key roles in regulating gene expression under hypoxia.

Methods

This study utilized an miRNA array to compare expression profiles under normoxic and hypoxic conditions. We analyzed 1,024 miRNAs, focusing on differentially expressed miRNAs. Survival analysis was performed using a cohort of 408 BC patients from TCGA (The Cancer Genome Atlas). Target prediction for hypoxia-inducible factors (HIFs) and cancer-related genes was performed.

Results

Of 1,024 miRNAs, 508 were downregulated and 516 upregulated in hypoxia. Four miRNAs (hsa-miR-210, hsa-miR-4435, hsa-miR-6875, hsa-miR-193b) were upregulated >50-fold, and four (hsa-miR-1250, hsa-miR-1288, hsa-miR-362, hsa-miR-6828) were downregulated. Upregulated miRNAs were associated with a trend toward improved overall survival in 408 BC patients (log-rank p = 0.049). Three downregulated miRNAs targeted HIF-1α, while three upregulated miRNAs targeted HIF-3α. Hsa-miR-210 targeted AGO2 and USP10, with hsa-miR-4435 also targeting AGO2.

Conclusion

BC under hypoxia exhibits a specific miRNA profile targeting HIFs and cancer-related genes including AGO2 and USP10, potentially influencing treatment success and survival.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder NeoplasmsMicroRNAsHypoxiaHumansGene Expression Regulation, NeoplasticFemaleHypoxia-Inducible Factor 1, alpha SubunitMaleUbiquitin ThiolesteraseCell HypoxiaAgedGene Expression ProfilingMiddle AgedRepressor ProteinsApoptosis Regulatory ProteinsArgonaute Proteins

Stichwörter der Autor:innen

Bladder cancerHypoxiaOncogenic pathwaysmiRNA

Substanzen

MicroRNAsHypoxia-Inducible Factor 1, alpha SubunitHIF1A protein, humanAGO2 protein, humanUbiquitin ThiolesteraseHIF3A protein, humanMIRN210 microRNA, humanRepressor ProteinsApoptosis Regulatory ProteinsArgonaute Proteins

Autor:innen und Institutionen

  • Department of Urology, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.
  • Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Japan, t-ina1@hama-med.ac.jp.

Zitieren

APA

Ohno, T., Nakajima, Y., Yoshikawa, Y., Tsujino, T., Maenosono, R., Nakamura, K., Takai, T., Uchimoto, T., Fukushima, T., Nishimura, K., Yano, Y., Higashio, T., Matsunaga, T., Nakamori, K., Azuma, H., & Inamoto, T. (2026). Hypoxia-Induced MicroRNAs Confer Survival Advantage in Bladder Cancer by Fine-Tuning Oncogenic Pathways. Oncology, 1-9. https://doi.org/10.1159/000551754

Vancouver

Ohno T, Nakajima Y, Yoshikawa Y, Tsujino T, Maenosono R, Nakamura K, et al. Hypoxia-Induced MicroRNAs Confer Survival Advantage in Bladder Cancer by Fine-Tuning Oncogenic Pathways. Oncology. 2026:1-9. doi:10.1159/000551754

BibTeX
@article{Ohno2026,
  author = {Ohno, Takaya and Nakajima, Yuki and Yoshikawa, Yuki and Tsujino, Takuya and Maenosono, Ryoichi and Nakamura, Ko and Takai, Tomoaki and Uchimoto, Taizo and Fukushima, Tatsuo and Nishimura, Kazuki and Yano, Yusuke and Higashio, Takuya and Matsunaga, Tomohisa and Nakamori, Keita and Azuma, Haruhito and Inamoto, Teruo},
  title = {Hypoxia-Induced MicroRNAs Confer Survival Advantage in Bladder Cancer by Fine-Tuning Oncogenic Pathways},
  journal = {Oncology},
  year = {2026},
  pages = {1--9},
  doi = {10.1159/000551754}
}
Kostenlos starten →